Ribomic Inc
TSE:4591

Watchlist Manager
Ribomic Inc Logo
Ribomic Inc
TSE:4591
Watchlist
Price: 81 JPY Market Closed
Market Cap: 3.3B JPY
Have any thoughts about
Ribomic Inc?
Write Note

Relative Value

The Relative Value of one Ribomic Inc stock under the Base Case scenario is 0.56 JPY. Compared to the current market price of 81 JPY, Ribomic Inc is Overvalued by 99%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.56 JPY
Overvaluation 99%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
22
Median 3Y
100.5
Median 5Y
123.2
Industry
8.1
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-5
Industry
23
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-5.5
Industry
23.4
vs History
vs Industry
Median 3Y
-4
Median 5Y
-5.4
Industry
27.3
vs History
82
vs Industry
61
Median 3Y
1.5
Median 5Y
2
Industry
2.6
vs History
14
vs Industry
85
Median 3Y
39.6
Median 5Y
72.2
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
vs Industry
27
Median 3Y
-1.3
Median 5Y
-2
Industry
4.3
vs History
vs Industry
25
Median 3Y
-1.3
Median 5Y
-2
Industry
3.8
vs History
vs Industry
28
Median 3Y
-1.5
Median 5Y
-2.6
Industry
6
vs History
vs Industry
25
Median 3Y
-1.5
Median 5Y
-2.6
Industry
3.8
vs History
80
vs Industry
70
Median 3Y
8.7
Median 5Y
17.3
Industry
4.8

Multiples Across Competitors

Competitors Multiples
Ribomic Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Ribomic Inc
TSE:4591
3.3B JPY 2 194.8 -3.5 -0.1 -0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
117.6B USD 4.2 933 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
JP
Ribomic Inc
TSE:4591
Average P/E: 216.8
Negative Multiple: -3.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
933
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
JP
Ribomic Inc
TSE:4591
Average EV/EBITDA: 18.1
Negative Multiple: -0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
JP
Ribomic Inc
TSE:4591
Average EV/EBIT: 23.5
Negative Multiple: -0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top